HEALTH● LOWAug 17 · Aug 17, 2026, 8:28 AM
Argenx advances as Vyvgart hits key trial endpoints for autoimmune myositis
Seeking Alpha Tech
A company's drug, Vyvgart, has met key trial endpoints for autoimmune myositis, indicating progress in its development for this condition. This represents a significant step in medical research for autoimmune diseases.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h agomRNA cancer vaccine helps reduce the chances of melanoma tumors returning4029tv.com · United StatesHEALTH1h agoPort Macquarie Base Hospital upgrade questioned by nurse | Port Macquarie Newsportnews.com.au · AustraliaHEALTH1h agoPsychiatrists seek home-grown research to tackle Africa’s mental health crisisVanguard NigeriaHEALTH3h agoAvoiding medical examinations, postponing surgery... The effects of childhood sexual abuse persist into adulthoodAsahi Shimbun